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Abstract
Objectives:  To determine the surgical and oncologic outcomes in patients who underwent retroperitoneoscopic
nephroureterectomy (RNU) in comparison to standard open nephroureterectomy (ONU) for upper urinary tract transitional
cell carcinoma (TCC).
Patients and methods: From April 2001 to January 2007, 60 total nephroureterectomy were performed for upper tract TCC
at Siriraj Hospital. Of the 60 patients, thirty-one were treated with RNU and open bladder cuff excision, and twenty-nine with
ONU. Our data were reviewed and analyzed retrospectively. The recorded data included sex, age, history of bladder cancer,
type of surgery, tumor characteristics, postoperative course, disease recurrence and progression.
Results: The mean operative time was longer in the RNU group than in the ONU group (258.8 versus 190.6 min; p = 0. < 001).
On the other hand, the mean blood loss and the dose of parenteral analgesia (morphine sulphate) were lower in the RNU group
(289.3 versus 313.7 ml and 2.05 versus 6.72 mg; p = 0.868 and p = 0.018, respectively). There were two complications in each
group. No significant difference in p stage and grade in both-groups (p = 0.951, p = 0.077). One patient with RNU had lymph
node involvement, three in ONU. Mean follow up was 26.4 months (range 3–72) for RNU and 27.9 months (range 3–63) for
ONU. No port metastasis occurred during follow up in RNU group. Tumor recurrence developed in 11 patients (bladder
recurrence in 9 patients, local recurrence in 2 patients) in the RNU group and 14 patients (bladder recurrence in 13 patients,
local recurrence in 1 patient) in the ONU group. No significant difference was detected in the tumor recurrence rate between
the two procedures (p = 0.2716). Distant metastases developed in 3 patients (9.7%) after RNU and 2 patients (6.9%) after ONU.
The 2 year disease specific survival rate after RNU and ONU was 86.3% and 92.5%, respectively (p = 0.8227).
Conclusion: Retroperitoneoscopic nephroureterectomy is less invasive than open surgery and is an oncological feasible
operation. Thus, the results of our study supported the continued development of laparoscopic technique in the management
of upper tract TCC.
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Background
The standard surgical procedure to treat upper urinary
tract transitional cell carcinoma (TCC) is open nephroure-
terectomy (ONU) with bladder cuff excision. However,
the morbidity of open surgery (e.g. severe pain and pro-
longed convalescence) is inevitable. In 1991, Clayman
firstly described the technique of laparoscopic nephroure-
terectomy (LNU), which was soon replicated by various
authors worldwide [1]. Recently, LNU through the
transperitoneal or retroperitoneal approach has been used
to treat upper urinary tract TCC, with reduced morbidity
[2]. Although the many other benefits of LNU are clear,
the application of these techniques to the treatment of
cancer raises issues relating to oncologic safety. Up to
date, most studies have shown the oncologic outcomes of
LNU comparable to ONU groups [3,4]. However, few
reports with adequate follow up in upper tract TCC
patients after retroperitoneoscopic nephroureterectomy
(RNU) have been published [5-7]. To determine whether
the surgical and oncologic outcomes of RNU is at least
equivalent to that of ONU, we present our 7 years experi-
ence of RNU with open bladder cuff excision, compared
with patients after ONU, in upper urinary tract TCC treat-
ment.
Patients and methods
From April 2001 to January 2007, 60 patients underwent
total nephroureterectomy with bladder cuff excision for
upper tract TCC at Faculty of Medicine Siriraj Hospital.
According to the decision of the surgeon's preference, 31
patients were treated with RNU, and 29 patients with
ONU. In all patients, the surgery was performed com-
pletely extraperitoneal with open bladder cuff technique.
Upper tract TCC was diagnosed by intravenous urogra-
phy, retrograde pyelography, computed tomography of
the abdomen, magnetic resonance imaging, and ureteros-
copy with or without biopsy. Preoperative cystoscopy and
radiologic examinations were performed to rule out
metastasis and concomitant bladder cancer.
LNU was performed using the retroperitoneal approach.
The patient was placed in a lateral position. After a retro-
peritoneal working space had been created, the pneu-
moretroperitoneum was maintained with carbon dioxide
gas at 10 mmHg. Three or four trocars were inserted in the
usual manner. The posterior peritoneum was mobilized
medially so that dissection of Gerota's fascia and the renal
pedicle could be fully performed. After the lymphatic
channels around the renal pedicle were excised to expose
the renal artery, this artery was isolated, clipped and
divided. The renal vein was mobilized and secured with
clips. Caudally, the fatty tissue around the ureter was
divided at the level of the iliac vessels crossing. Finally the
kidney was completely mobilized. Lymphadenectomy
was performed at surgeon's discretion. The patient posi-
tion was then changed to supine. An approximately 7 cm
long Gibson's incision was made, and the distal ureter
with a bladder cuff specimen was removed en bloc with-
out opening the urinary tract. If the cancer was located in
the mid or distal ureter, lymphadenectomy was consecu-
tively performed around the lesion.
The standard ONU was performed using a flank incision.
The distal ureter management was performed as standard
technique. All patients with concomitant bladder tumor
were underwent transurethral resection concomitantly.
All patients with proven nodal disease were counseled for
adjuvant therapy. Patients have a follow-up cystoscopy
every 3 months in the first 2 years, every 6 months in the
following 3 years and annually after 5 years.
We retrospectively reviewed our database and extracted
data on the following variables: sex, age at diagnosis, his-
tory of previous bladder cancer, type of surgery, complica-
tions, tumor characteristics, postoperative course, disease
recurrence and disease progression.
The comparison between the two groups was carried out
using the Mann-Whitney U test and Fisher's exact test.
Time to recurrence was evaluated from the date of surgery.
Recurrence free survival was defined as the interval from
surgery to the first tumor recurrence, the detection of dis-
tant metastases or the end of the study. Survivals were ana-
lyzed by the Kaplan-Meier method. To assess the effect of
type of surgery on time to recurrence after adjusting for
the effects of pathological stage and grading, a Cox's pro-
portional hazard model was fitted. For all statistical tests,
P < 0.05 was considered to indicate a significant differ-
ence.
Results
The characteristics of the patients who underwent RNU
and ONU are shown in Table 1. There was no significant
difference in mean age (p = 0.353), operative side (p =
0.796), tumor location (p = 0.233), and concomitant or
history of bladder cancer (p = 0.599).
A comparison of the perioperative parameters between
the two groups is shown in Table 2. No significant differ-
ences were founded in blood transfusion, mean time to
first diet, length of indwelling urethral catheter, and hos-
pital stay. The mean operative time was significant longer
in the RNU group (p = <0.001). However, although not to
a significant extent, the mean blood loss tended to be less
in the RNU group (289 vs. 313 ml).
Additionally, the dose of parenteral analgesia was signifi-
cantly reduced in RNU group (p = 0.018). Complications
developed in 2 patients of each group. In the RNU group,World Journal of Surgical Oncology 2008, 6:3 http://www.wjso.com/content/6/1/3
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one patient had ischemic heart disease which required
coronary angiography. Another patient had postoperative
urinary tract infection and required parenteral antibiotic
with prolonged hospital stay. In the ONU group, one
patient had postoperative bleeding which required open
surgery to stop bleeding. Another patient had an urinoma
at perivesical space and required surgical drainage.
The oncologic results are shown in Table 3. There were no
statistical difference in tumor stage and grade in both
groups (p = 0.951 and p = 0.077, respectively). Lym-
phadenectomy was performed in 20 patients (64.5%)
with RNU and 9 patients (31.0%) with ONU groups. One
patient in each group was found to have a single lymph
node micrometastasis. Both patients were managed con-
servatively due to refuse chemotherapy and further fol-
low-up to 30, 31 months respectively showed no evidence
of disease recurrence. Another two patients in ONU group
had multiple lymph node metastasis. One patient devel-
oped bone metastasis after 8 months despite adjuvant sys-
temic chemotherapy. Another patient, with large
persisting lymph node at resection site, died of to tumor
progression after 7 months. It was noted that this patient
had no adjuvant therapy due to poor performance status.
There was no port site metastasis occurred during follow
up in RNU group. Bladder cancer recurrence occurred in 9
patients (29%) in the RNU group and 13 patients
(44.8%) in the ONU group. No statistically significant dif-
ference was observed (P = 0.285). Local recurrence devel-
oped in 2 patients in the RNU group and 1 patient in the
ONU group, in 2 of whom distant metastases in the lung
and bone were detected simultaneously. All three patients
had a negative surgical margin on histopathological
examination. The metastasis rate was 9.7% (3/31) after
RNU and 6.9% (2/29) after ONU (p = 1.00). The median
Table 1: Patient characteristics
Variable Number (%) or Mean (Min-Max)
RNU (N = 31) ONU (N = 29) P Value
Age, years 63.8 (26–79) 66.8 (39–88) 0.353
Sex
Male 11 (35.5) 22 (75.9)
Female 20 (64.5) 7 (24.1)
Side
Left 18 (58.1) 15 (51.7) 0.796
Right 13 (41.9) 14 (48.3)
Tumor location
Renal pelvis 14 (45.2) 10 (34.5) 0.233
Ureter 13 (41.9) 10 (34.5)
Multifocal 4 (12.9) 9 (31)
Concomitant or history of bladder cancer 11 (35.5) 13 (44.8) 0.599
Table 2: Surgical results
Variable Mean (Min-Max) or Number (%)
RNU (N = 31) ONU (N = 29) P Value
Operative time (min) 258.87 (90–425) 190.69 (105–360) <0.001*
Blood loss (ml) 289.35 (100–800) 313.79 (50–800) 0.868
Blood transfusion 6 (19.3) 7 (24.1) 0.758
Time to first diet (days) 1.13 (1–2) 1.10 (1–2) 1.000
Time to remove of urethral 
catheter (days)
6.81 (2–16) 6.24 (1–11) 0.727
Hospital stay (days) 9.32 (6–20) 8.69 (5–13) 0.890
Parenteral analgesia
Morphine sulphate (mg) 2.05 (0–10) 6.72 (0–35) 0.018*
Complication
Ischemic heart disease 1 0
Urinary tract infection 1 0
Re-explor (bleeding) 0 1
Urinoma 0 1World Journal of Surgical Oncology 2008, 6:3 http://www.wjso.com/content/6/1/3
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time to metastasis was 12 months (range 6–14) and 14
months (range 8–20) in the RNU and ONU groups,
respectively. For the RNU group, three patients died of dis-
tant metastasis (two in the liver, one in the lung) and one
patient died of cardiac disease during the follow up
period. For the ONU group, two patients died of disease
progression (one in the lung, one in the lymph node) and
two patients died from other causes unrelated to tumor.
The median time to recurrence was 40 months (range 3–
71) and 23 months (range 3–63) in the RNU and ONU
groups, respectively. The prognostic factors studied by
multivariate analysis given in Table 4. Analysis results
revealed that even though ONU seemed to have a higher
risk of recurrence than RNU (HR = 1.50, 95% CI = 0.67,
3.35) there was no statistical difference (p = 0.323). There
was also no significant effect of stage (stage 2: HR = 1.15,
p = 0.776; stage 3: HR = 2.58, p = 0.144) and grade (High:
HR = 1.21, p = 0.701) on recurrence. For recurrence free
survival analysis, we found no statistically significant dif-
ference between the two procedures (p = 0.2716) (Fig.
1A). Additionally, we found no statistically significant dif-
ference in recurrence free survival curves between the two
procedures in terms of p stage and grade (Fig. 1B–E). The
mean follow up time of the RNU group and the ONU
group was 26.4 months (range 3–72) and 27.9 months
(range 3–63) respectively. No significant difference was
found between the two procedures with regard to disease
specific and overall survival (Fig. 2A, B). The 2 years dis-
ease specific survival rate was 86.3% in the RNU group
and 92.5% in the open group (P = 0.8227). The corre-
sponding 2 years overall survival rate was 86.3% and
83.3% (P = 0.8628).
Discussion
Laparoscopic nephroureterectomy was developed in an
effort to reduce the morbidity of the surgical manage-
ment. Indeed, several investigators have recently sug-
gested their benefit for patient recovery with disease
control comparable to that of traditional open surgery [2-
4]. The mean oral diet day, urethral catheter time, and
hospital stay were equivalent in the both groups in our
series. However, the operative time was longer in the
laparoscopic groups. On the other hand, the blood loss
and the dosage of analgesia were lower after laparoscopic
nephroureterectomy. In a literature review of 1365 neph-
roureterectomy patients, Rassweiler et al. reported the
operative time (277 vs. 220 min) and the blood loss (241
vs. 463 ml.) comparing between the laparoscopic series
and open series [2]. These findings correspond to our
results and support the effectiveness of laparoscopic pro-
cedure compared with the standard open procedure.
Laparoscopic nephroureterectomy can be performed via a
transperitoneal or retroperitoneal access. We used the ret-
roperitoneal approach. Although the operating space is
smaller and a more skilled technique is required than with
the transperitoneal approach, the advantage of retroperi-
toneal approach in avoiding intraabdominal injury and
tumor spillage into intraabdominal cavity are our consid-
eration. Rouprêt et al. reported the complications of
colonic injury after transperitoneal LNU [4]. We found no
complication of intraabdominal injury and two minor
complications after retroperitoneal LNU in our series.
These finding confirmed the benefit of retroperitoneal
approach and a feasible technique for LNU. Additionally,
Table 3: Oncologic results
Variable Number (%) or Mean (Min-Max)
RNU (N = 31) ONU (N = 29) P Value
Pathologic stages
T1 16(51.6) 13 (44.8) 0.951
T2 10 (32.3) 12 (41.4)
T3 4 (12.9) 4 (13.8)
T4 1 (3.2) 0 (0.0)
Grade
Low 18 (58.1) 10 (34.5) 0.077
High 13 (41.9) 19 (65.5)
Node 20 (64.5) 9 (31.0)
Negative 19 (95) 6 (66.7) 0.076
Positive 1 (5) 3 (33.3)
Recurrence 11 (35.4) 14 (48.2) 0.300
Bladder 9 (29.0) 13 (44.8) 0.285
Local 2 (6.4) 1 (3.4)
Metastasis 3 (9.7) 2 (6.9) 1.000
Follow up time (months) 26.4 (3–72) 27.9 (3–63) 0.534
2 yr. disease specific survival 86.3% 92.5% 0.8227
2 yr. overall survival 86.3% 83.3% 0.8628World Journal of Surgical Oncology 2008, 6:3 http://www.wjso.com/content/6/1/3
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the technique of ureterectomy and bladder cuff excision
has not been standardized yet. A number of minimal inva-
sive approaches to the distal ureter such as endoscopic
stripping or pluck-off techniques have been reported [8-
11]. However, these endoscopic techniques have a greater
risk of local recurrence and stone formation in the staple
lines [12]. We prefer open distal ureterectomy and blad-
der cuff excision. This method avoids the risk of urinary
leakage and allows for intact specimen removal. We
believed this will not adversely affect patient's recovery
compared with the endoscopic approach. Furthermore,
there are no contraindications such as ureteral tumors or
periureteral fibrosis due to previous surgery, irradiation or
inflammatory pelvic disease [13]. The worldwide reported
bladder recurrence rate was 9–48% with different meth-
ods for controlling the bladder cuff [2,14,15]. In our
series, the bladder recurrence rate (29%) after RNU was
within the reported range. In addition, the problem of
port site metastasis in laparoscopic procedure is impor-
tant. Rassweiler et al. reported that six port site metastasis
in 377 (1.6%) analyzed patients following laparoscopy
were recognized [2]. Recently, Schatteman et al. reported
another three cases of port metastasis after laparoscopy
[16]. In most cases, extraction of the specimen was per-
formed without an organ or with a torn organ bag. In our
series, no case of port site metastasis was observed during
the follow up period. We routinely avoid the use of har-
monic scalpel for tissue dissection which might be an ori-
gin of tumor cell spreading as previously described [17]
and we retrieved the intact specimen via the open wound.
The indication for laparoscopic nephroureterectomy in
upper tract TCC is not yet well defined. Although most
authors still recommended that high stage and grade
tumors should be contraindications to LNU [2,3,5].
Recently in 2007, Muntener et al. reported oncologic out-
come after LNU with a median follow up time of 74
months and supported the LNU as the standard of care for
high grade or high stage upper tract TCC [18]. In our
series, we found no statistically significant difference in
recurrence free survival curve between both procedures in
terms of tumor grade and stage (Fig. 1B–E). However, we
believe that the indication tend to increase as surgical skill
developed in laparoscopic treatment and we could have
identified additional candidates with high grade or high
Recurrence free survival according to surgical procedure (A), stage (B, C), grade (D, E) Figure 1










P=0.3044 World Journal of Surgical Oncology 2008, 6:3 http://www.wjso.com/content/6/1/3
Page 6 of 7
(page number not for citation purposes)
stage tumor for LNU if accurate staging with preoperative
imaging and biopsy had been done.
McNeill et al. reported favorable long term outcomes after
LNU compared with ONU; however, information on
nodal status was available in only 4% of cases [19]. Klin-
ger et al. found micrometastasis in 14.3% (2 of 14) of clin-
ical No patients and advised to perform
lymphadenectomy routinely for staging purpose [17]. In
our series, lymphadenectomy was performed in 48.3%
(29/60) of cases. We had no definitive criteria for choos-
ing the surgical procedure, including the indication for
lymphadenectomy, which might affect the results of treat-
ment. We found micrometastasis in 2 patients and these
patients are still alive until the last follow up time. How-
ever, the prospective randomized study is needed to sup-
port the benefit and efficacy of routine laparoscopic
regional lymphadenectomy.
In 2000 Gill et al. reported retroperitoneoscopic neph-
roureterectomy with bladder cuff excision through a trans-
vesical approach and at a mean follow up of 11 months
the cancer specific survival rate was 97% in the LNU group
[20]. Hsueh et al. reported Hand assisted RNU with open
bladder cuff excision compare to ONU [7]. The study
showed no significant difference in terms of the disease
specific and overall survival rate between the two groups.
In 2007, Manabe et al. reported oncologic outcome of
LNU with the same surgical approach as in our study. The
study showed the 2 years disease specific survival rate were
similar in both groups (85.2 vs 87%) [21]. The worldwide
reported disease survival was 72–95% with different
methods for LNU and distal ureter management
[16,17,22]. In the present series shows a 2 years disease
specific survival of 86.3% which is comparable to litera-
ture data. No significant difference in disease specific and
overall survival curve were found between both proce-
dures. These results confirmed the oncologic safety of ret-
roperitoneoscopic nephrectomy compared with the
standard ONU.
Conclusion
The retroperitoneoscopic nephroureterectomy with open
bladder cuff excision seems to be a safe alternative treat-
ment for upper urinary tract TCC and offers the advan-
tages of laparoscopic procedure. From the oncologic stand
point, it is not associated with an increased risk of tumor
recurrence compared with the standard open neprhoure-
terectomy. Because of limitation in retrospective study,
thus a true prospective and continued evaluation of
longer follow up data are needed before RNU should
become the new standard of care for the upper tract TCC.
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